Ensol Biosciences was founded in 2001 and listed on KONEX in 2018, and it is headquartered in Daejeon. The company develops short peptides that modulate protein-protein interactions.
It promotes its signal-path selective regulation (SSR) technology, which is meant to block only pathological signals, together with an AI-based candidate discovery platform.
Its core pipeline is P2K for degenerative disc disease, E1K for knee osteoarthritis and C1K for triple-negative breast cancer, followed by M1K for Alzheimer's disease and H1K, an oral obesity candidate.
Spine Biopharma of the United States leads global development of P2K. Yuhan ran the early domestic trials, and in 2018 Yuhan transferred exclusive rights to Spine Biopharma. According to earlier press reports, Ensol Biosciences receives 25% of the upfront payments and milestones under that arrangement.
In July 2024 the company signed a further license covering indications such as osteoarthritis, fibrosis and tumors, and its corporate history lists a total contract value of KRW 215.4 billion.
E1K is a synthetic peptide that selectively modulates the TGF-β1 signaling pathway to curb cartilage degeneration. The domestic Phase 3 targets 363 knee osteoarthritis patients and uses LG Chem's Synovian as the comparator.
Leaders Cosmetics holds the domestic distribution rights, and the company envisions a partner leading overseas trials after a license deal. The company says it first demonstrated efficacy through an animal osteoarthritis product.
Revenue remains small relative to the research effort. According to a data provider, revenue was split between animal pharmaceuticals at 77.26% and CMC synthesis and analytical services at 22.74%. The center of gravity is therefore license upfronts, milestones and royalties rather than product sales.
Unlike a large pharmaceutical company such as Yuhan with an established revenue base, results here depend on clinical outcomes and partner contracts.